PROSTVAC, an active immunotherapy vaccine, can induce the immune response of tumor-infiltrating T-cells by targeting prostate-specific antigen (PSA) and demonstrates high potency and low adverse effects against PCa patients with low disease burden and indolent disease (Gulley et al., 2019). Here, KLK3 is linked to neoplasm.